<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:content="http://purl.org/rss/1.0/modules/content/"
  xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Molecular Neuroimaging — Health News</title>
    <link>https://molecular-neuroimaging.com/health-news/</link>
    <description>New papers and conference findings in brief: measured claims, stated limitations, links to the source.</description>
    <language>en-US</language>
    <lastBuildDate>Wed, 18 Nov 2026 04:58:46 GMT</lastBuildDate>
    <atom:link href="https://molecular-neuroimaging.com/health-news/feed.xml" rel="self" type="application/rss+xml" />
    <category>Health News</category>
    <item>
      <title>What Medicare Enrollment Means for a Dedicated Brain PET Clinic</title>
      <link>https://molecular-neuroimaging.com/health-news/medicare-enrollment-means-dedicated-brain-pet-clinic/</link>
      <guid isPermaLink="true">https://molecular-neuroimaging.com/health-news/medicare-enrollment-means-dedicated-brain-pet-clinic/</guid>
      <description><![CDATA[Grey Matters Health's Florida clinic can now bill public insurers — the practical step that turns a scanner into a service.]]></description>
      <content:encoded><![CDATA[<p>Can a clinic built around a single purpose — scanning the brain for signs of Alzheimer's disease — actually reach patients at scale? On November 16, 2026, Grey Matters Health Inc. (CSE: GREY) announced that its NovaScan Neuroimaging Clinics location in Davie, Florida has attained accreditation and completed full enrollment in both Medicare and Medicaid, according to a report by <a href="https://kalkinemedia.com/ca/news/announcements/grey-matters-health-achieves-accreditation-and-medicaremedicaid-enrollment-for-florida-based-novascan-neuroimaging-clinics" rel="nofollow noopener" target="_blank">Kalkine Media</a>. In plain terms, the clinic can now bill public insurance for its brain PET scans.</p><p>That matters because, per the announcement, Medicare, Medicaid and most private insurers already cover brain PET scans for beta-amyloid plaque detection in patients aged 65 and older. Enrollment is the bridge between that coverage rule and an actual appointment. Without it, a scanner sits idle for the very population most likely to be referred. More on the health news context below. For related coverage, see <a href="https://molecular-neuroimaging.com/health-news/alzheimers-symptoms-stage-by-stage/">Alzheimers Symptoms Stage by Stage: What Clinicians Notice</a>.</p><h2>What does accreditation actually test?</h2><p>Accreditation from a recognized U.S. regulatory authority is a prerequisite for diagnostic imaging centers seeking Medicare reimbursement and in-network status with private insurers. According to the announcement, the process examined three things: radiation dose management, diagnostic image quality, and staff credentials — the licensing and certifications of radiologists, medical physicists and technologists.</p><p>The company frames this as reassurance for referring physicians: that the center produces high-quality images, employs qualified professionals, and follows established patient-safety standards. That framing is the company's own, but the underlying logic is standard for U.S. imaging: an accreditor checks the inputs — dose, quality, personnel — so payers do not have to.</p><h2>Why the scanner itself is the interesting part</h2><p>The Davie facility will use the CareMiBrain system, a U.S. FDA-cleared PET scanner dedicated to the brain. Its design is unusual: a chair-styled device with no integrated computed tomography (CT) component. CT is normally bundled into PET scanners to help with image correction and positioning, but it adds radiation dose. The company states that dropping the CT reduces patient radiation exposure by 25%.</p><p>For readers following imaging technology, the design choice signals where brain imaging may be heading: machines optimized for one organ rather than whole-body generalists. Readers interested in the hardware side can follow the site's imaging technology coverage. The company describes the Davie site, located in the HCA Florida University Medical Office Building, as the first U.S. center offering brain-dedicated PET scans for Alzheimer's disease detection — a claim from the announcement, not an independent audit.</p><h2>What this does and does not change for patients</h2><p>Public enrollment means eligible Americans covered by Medicare or Medicaid can, in principle, access the clinic's specialized brain PET services with billing under established codes for brain PET scans and related isotopes. That is the commercial milestone the company is highlighting. This connects to our earlier piece, <a href="https://molecular-neuroimaging.com/health-news/memory-loss-icd-10-who-codes-explained/">Memory Loss ICD 10 Classification: How WHO Codes Work</a>.</p><p>What it does not change: private insurers. The announcement notes that investors are watching for updates on in-network contract negotiations with private payers, and for plans to add clinic locations. The company's stated long-term objective is a network of dedicated brain PET imaging clinics across the United States, but the release provided no specific timelines or financial details. Treat the expansion as an intention, not a schedule.</p><h2>The open question</h2><p>The honest reading of this announcement is procedural rather than scientific. Nothing here reports new imaging performance, new diagnostic accuracy, or new clinical evidence. What it reports is infrastructure: a clinic cleared to serve publicly insured patients using an FDA-cleared device. The open question is demand — whether referring physicians will route enough patients to a single-site, brain-only scanner to justify the network the company envisions. Coverage rules for amyloid PET in patients 65 and older give the clinic a defined market; whether that market shows up is what the next announcements will need to demonstrate.</p>]]></content:encoded>
      <pubDate>Wed, 18 Nov 2026 04:57:00 GMT</pubDate>
      <dc:creator>Victor Petrov</dc:creator>
      <category>Health News</category>
      <enclosure url="https://nyc3.digitaloceanspaces.com/vuga/autopublish/molecular-neuroimaging/d928db282e0c82294d9d72f27d69747dcb3fcdab4d1790d913135c7fa91f9e85/1200w.webp" type="image/jpeg" length="0" />
    </item>
    <item>
      <title>Alzheimers Symptoms Stage by Stage: What Clinicians Notice</title>
      <link>https://molecular-neuroimaging.com/health-news/alzheimers-symptoms-stage-by-stage/</link>
      <guid isPermaLink="true">https://molecular-neuroimaging.com/health-news/alzheimers-symptoms-stage-by-stage/</guid>
      <description><![CDATA[Alzheimers symptoms start with memory problems and deepen through stages. Clinicians track ten warning signs, federal health institutes report.]]></description>
      <content:encoded><![CDATA[<p>Alzheimers symptoms often begin quietly, with memory problems at the front of the line. The National Institute on Aging calls memory loss one of the first signs. Trouble finding words can also arrive early. So can trouble judging space and reason. Over years the pattern deepens through mild, moderate and severe stages. Doctors watch for ten warning signs rather than one forgotten name. What follows is a stage-by-stage map of what they see.</p><p>Scope matters before any list of Alzheimers symptoms. Alzheimer's is the most common form of dementia. The World Health Organization counted 57 million people living with dementia in 2021. Alzheimer's may contribute to 60 to 70 percent of cases. The CDC tracks the United States count. It stood at 6.9 million in 2020. The agency expects about 14 million by 2060. Dementia, the CDC stresses, is not a set part of ageing. That scale is why clear public signs matter.</p><h2>Alzheimers Symptoms: The Ten Warning Signs</h2><p>The Alzheimer's Association lists ten early signs. Memory loss that disrupts daily life leads the list. Trouble planning or solving problems comes next. Trouble finishing familiar tasks counts too. Confusion about time or place follows. So does trouble reading images and space. New problems with words, spoken or written, also count. Losing things makes the list. Poor judgment makes it as well. Pulling back from social life counts too. Mood shifts close the list. Each sign alone is thin. Several together form a pattern. The contrast with normal aging is one of degree. Forgetting a name now and then is common at any age. Forgetting new facts again and again is not. We covered a connected angle in <a href="https://molecular-neuroimaging.com/research-watch/implicit-vs-explicit-memory-two-systems-one-brain/">Implicit vs Explicit Memory: Two Systems, One Brain</a>.</p><h2>Normal Aging or Early Disease: The Line Doctors Draw</h2><p>Doctors draw the line by daily function. Normal slips annoy. Disease-level changes disable. One missed bill can happen to anyone. Losing the ability to manage money at all signals something more. The CDC adds a useful caution. Several signs together still do not confirm Alzheimer's. Only a full clinical exam can do that. Families often spot the pattern before any clinic does. Group numbers describe groups, never one person's future.</p><h2>How Symptoms Change Across Stages</h2><p>Alzheimers symptoms deepen along a rough path. The National Institute on Aging describes it in four stages. Preclinical Alzheimer's comes first. Brain changes run beneath normal thinking at that point. The mild stage, sometimes called early-stage, brings memory lapses. Word-finding trouble comes with it. Moderate disease adds deeper confusion. Behavior shifts and mood changes join in. The severe stage leaves daily care needs high. Most people with the late-onset form first show symptoms in their mid-60s. Some show them later. Early-onset disease, before 65, is rarer. It can begin in a person's 30s. The stages are a rough path, not a strict script. Each person moves through them at their own pace. For related coverage, see <a href="https://molecular-neuroimaging.com/brain-health/memory-care-facilities-what-they-are-how-to-evaluate/">Memory Care Facilities: What They Are and How to Evaluate Them</a>.</p><h2>What Symptoms Alone Cannot Confirm</h2><p>A symptom map is not a diagnosis. Memory trouble has many causes. MedlinePlus, the federal health library, lists some of them. Strokes are one. Depression is another. Head injuries and thyroid trouble also belong on the list. So do reactions to certain medicines. Each cause points to different care. A clinical workup exists to sort these apart. It also separates Alzheimer's from other dementias. Those other forms need their own kind of care. That is why institutes recommend an exam rather than a self-check. The signs are a reason to ask, not a verdict.</p><h2>Conclusion: Why Early Spotting Matters</h2><p>Spotting Alzheimers symptoms early opens doors that late spotting closes. An early exam can catch treatable causes first. Medicine effects and thyroid trouble are two of these. Research on care and future treatments depends on finding people in time. The rising case counts add urgency to that slow clinical work. The open question is whether spotting can outrun the rising numbers. For now, the ten signs remain the best public map of the disease's first moves.</p>]]></content:encoded>
      <pubDate>Wed, 15 Apr 2026 13:25:00 GMT</pubDate>
      <dc:creator>Victor Petrov</dc:creator>
      <category>Health News</category>
      <enclosure url="https://nyc3.digitaloceanspaces.com/vuga/autopublish/molecular-neuroimaging/4f3b73448667c5dfddfc5d56c6a9a4fdafc00cf0c2679595325af8cd1b9c4df4/1200w.webp" type="image/jpeg" length="0" />
    </item>
    <item>
      <title>Memory Loss ICD 10 Classification: How WHO Codes Work</title>
      <link>https://molecular-neuroimaging.com/health-news/memory-loss-icd-10-who-codes-explained/</link>
      <guid isPermaLink="true">https://molecular-neuroimaging.com/health-news/memory-loss-icd-10-who-codes-explained/</guid>
      <description><![CDATA[Memory loss ICD 10 coding starts at R41.3, Other amnesia. WHO codes separate symptoms from Alzheimer disease and dementia diagnoses.]]></description>
      <content:encoded><![CDATA[<p>Memory loss ICD 10 coding starts with a code called R41.3. The World Health Organization titles the code Other amnesia. It belongs to the tenth revision of the International Classification of Diseases. That revision is the global standard for naming health problems. Codes never treat anyone. Their job is exact wording for records, counts and research. A code states one thing with care. It names what the record calls the problem. Reading the codes shows how a complaint becomes a label.</p><p>The system rewards a careful reader. The reward is precision. A symptom code and a disease code can describe the same person on the same day. One chapter gathers symptoms, another gathers diagnoses. Following that path shows where memory loss sits in the WHO map of medicine. Readers following this should also see <a href="https://molecular-neuroimaging.com/health-news/alzheimers-symptoms-stage-by-stage/">Alzheimers Symptoms Stage by Stage: What Clinicians Notice</a>.</p><h2>What the ICD 10 System Does</h2><p>The tenth revision, known as ICD-10, gives every condition a short code of letters and digits. Chapters group related items, from infections to injuries. The World Health Organization maintains the revision. It publishes the codes in an online browser. Each code carries a strict title. One example is R41, other symptoms and signs involving cognitive functions and awareness. Shared codes let hospitals in different nations report the same condition the same way. The same string of characters means the same thing in every country. Nations can then pool their numbers with confidence. Health statistics rest on that shared tongue.</p><h2>Memory Loss ICD 10 Codes: The Symptom Level</h2><p>At the symptom level, memory loss ICD 10 work lands on R41.3. The browser lists R41.3 as a leaf code titled Other amnesia. A code reads like a postal address. The letter names the chapter, and the digits narrow the street. Leaf codes sit at the end of a branch. Nothing sits beneath them. No finer codes open up under R41.3. The branch simply ends there. Vague forgetfulness maps here before any diagnosis exists. The symptom chapter never claims a cause. It records what a clinician saw, nothing more. That restraint is the design, not a gap.</p><h2>From Symptom to Diagnosis: G30 and F00</h2><p>Diagnosis codes tell the deeper story. G30 carries the exact title Alzheimer disease in the WHO browser. It lives among disorders of the nervous system. F00, titled Dementia in Alzheimer disease, sits in the mental and behavioral chapter. The pairing is no accident. G30 names the brain disease itself. F00 names the dementia it produces. Clinicians often code both once an exam is complete. Both codes can sit on one record. G30 and F00 often travel in pairs.</p><h2>How Clinicians Apply the Codes</h2><p>Coding follows the purpose of a visit. That purpose drives the choice. A first appointment may carry R41.3 while tests are pending. A memory clinic may later add G30 with F00 after a diagnosis. Memory complaints have many sources, as the federal library MedlinePlus notes. Strokes carry one code. Depression carries another. Head injuries and drug reactions carry their own as well. Insurers read the codes too, in countries that bill by them. Planners read them when sizing clinics. The sorting quietly powers research. A code is a tool with many readers. The World Health Organization counted 57 million dementia cases for 2021 using such labels. Shared codes are what make a worldwide number possible.</p><h2>Conclusion: Codes Before Treatment</h2><p>Memory loss ICD 10 entries are the map, not the ground. R41.3 marks the complaint, G30 the disease, F00 the dementia. The codes show how medicine sorts a vague worry into countable boxes. What they do not show is cause, treatment or outlook. Those answers live in clinics and trials, beyond the browser window. Codes come before care, not instead of it. A person still needs an exam and a clinician's judgment. The open question is how the codes will track memory disorders as tests get sharper.</p>]]></content:encoded>
      <pubDate>Sat, 31 Jan 2026 11:25:00 GMT</pubDate>
      <dc:creator>Victor Petrov</dc:creator>
      <category>Health News</category>
      <enclosure url="https://nyc3.digitaloceanspaces.com/vuga/autopublish/molecular-neuroimaging/c5ec1b65129a540bbc8737dc94292ab823994764e65933ac6ac269d77f296500/1200w.webp" type="image/jpeg" length="0" />
    </item>
  </channel>
</rss>